Kcentra Dosing for Apixaban Reversal
For patients requiring reversal of apixaban (Eliquis), the recommended dose of Kcentra (4-factor prothrombin complex concentrate) is 50 units/kg for life-threatening bleeding, with a lower dose of 25 units/kg considered for less severe bleeding. 1, 2
Dosing Algorithm for Apixaban Reversal
Assessment Phase
Determine severity of bleeding:
- Life-threatening or critical organ bleeding (intracranial, intraspinal, intraocular, retroperitoneal)
- Major non-life-threatening bleeding
- Minor bleeding
If available, assess apixaban plasma concentration:
- Consider reversal if levels >50 ng/mL with serious bleeding
- Consider reversal if levels >30 ng/mL with need for urgent procedure 2
Reversal Protocol
First-line agent (when available):
- Andexanet alfa is the FDA-approved specific reversal agent for apixaban 1, 2
- Low dose: 400 mg IV bolus over 15 min followed by 480 mg infusion over 2 hours
- High dose: 800 mg IV bolus over 30 min followed by 960 mg infusion over 2 hours
When andexanet alfa is unavailable:
- For life-threatening bleeding: Kcentra 50 units/kg IV (maximum 5,000 units) 1, 2
- For major non-life-threatening bleeding: Kcentra 25 units/kg IV 1, 3
- For minor bleeding: Local hemostatic measures without reversal agent
Important Considerations
Monitoring
- Monitor for thrombotic complications after administration
- Follow hemoglobin, vital signs, and bleeding status
- Consider repeat imaging for intracranial hemorrhage
Thrombotic Risk
- PCCs like Kcentra carry increased risks of both venous and arterial thrombosis during the recovery period 3
- Begin thromboprophylaxis as early as possible after bleeding control is achieved 3
Efficacy Evidence
- Studies show that 4F-PCC (Kcentra) at doses of 25-50 units/kg can effectively reverse apixaban-associated bleeding 4, 5, 6
- In a rabbit model, doses ≥12.5 IU/kg showed significant reversal of bleeding volume 4
- Clinical studies have shown approximately 72-75% achievement of effective hemostasis with 4F-PCC in patients with apixaban-associated major bleeding 5, 7
Limitations
- PCCs do not truly "reverse" Xa inhibitors but provide coagulation factors that may overcome the anticoagulant effect 3
- Laboratory studies show PCCs may not fully reverse anti-Xa activity 3
Practical Application
- Administer as soon as possible after determining need for reversal
- Reconstitute according to manufacturer's instructions
- Infuse at a rate not exceeding 8.4 mL/min (210 units/min)
- Consider additional hemostatic measures if bleeding persists
Remember that while Kcentra is not FDA-approved specifically for apixaban reversal, it is commonly used when andexanet alfa is unavailable, with evidence supporting its effectiveness in achieving hemostasis in patients with apixaban-associated major bleeding.